Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Waldenstrom Macroglobulinemia × Clonal Evolution × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

Rituximab 93 Cyclophosphamide 53 fludarabine phosphate 45 Peripheral Blood Stem Cell Transplantation 41 Bortezomib 31 Mycophenolic Acid 30 Whole-Body Irradiation 29 ibrutinib 28 Dexamethasone 27 Cyclosporine 21 Tacrolimus 20 Etoposide 19 zanubrutinib 18 Filgrastim 18 Melphalan 17 Lenalidomide 17 Busulfan 17 Radiotherapy 16 Methotrexate 14 Antilymphocyte Serum 14 Bendamustine Hydrochloride 13 Sirolimus 11 Calcium Dobesilate 11 Everolimus 9 venetoclax 8 ibritumomab tiuxetan 8 Prednisone 8 Indium 8 Cytarabine 8 Cyclosporins 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡